Antiarrhythmic agents. I. Mechanisms of action and clinical pharmacology.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001949:Bretylium Compounds / Q000494:pharmacology / Q000627:therapeutic use; D004594:Electrophysiology; D006321:Heart / Q000502:physiology; D006329:Heart Conduction System / Q000502:physiology; D006801:Humans; D007700:Kinetics; D008012:Lidocaine / Q000494:pharmacology / Q000627:therapeutic use; D008566:Membranes / Q000502:physiology; D010672:Phenytoin / Q000627:therapeutic use; D011188:Potassium / Q000627:therapeutic use; D011342:Procainamide / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011802:Quinidine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D012032:Refractory Period, Electrophysiological
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D010672:Phenytoin; D008012:Lidocaine; D011433:Propranolol; D011802:Quinidine; D011342:Procainamide; D011188:Potassium